7 months ago
NVO
AnalystsJames QuigleyJames Quigley's Stock Forecasts
AnalystsJames Quigley
Analyst Ranking
Top 33%
#1790 out of 5511 analysts
Average Return
+45.7%
Win Rate
57%4 out of 7
Risk vs Reward
Poor
Good
James Quigley's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Morphosys AgMOR | +191.69% | $6.50 | $18.96 | 2023-10-13 - 2024-08-02 | Strong Buy |
Ablynx NvABLX | +129.87% | $23.00 | $52.87 | 2017-11-20 - 2018-06-12 | Strong Buy |
Kymera Therapeutics IncKYMR | +63.58% | $43.58 | $71.29 | 2025-06-03 - 2026-06-02 | Strong Buy |
Kymera Therapeutics IncKYMR | +30.24% | $86.88 | $113.15 | 2025-12-09 - 2026-09-15 | Strong Buy |
James Quigley Analyst Color
Get additional color on James Quigley's coverage of popular stocks
a year ago
NVS
James Quigley's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Novo Nordisk A SNVO | 2 | Hold | $41.00 | -3.60% | Downgrades | 7 months ago |
Kymera Therapeutics IncKYMR | 7 | Strong Buy | $127.00 | +12.24% | Maintains | 9 months ago |
Novartis AgNVS | 2 | Strong Sell | $118.00 | N/A | Downgrades | a year ago |
SanofiSNY | 1 | Hold | $65.00 | N/A | Initiates Coverage On | a year ago |
Morphosys AgMOR | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Grifols SaGRFS | 1 | Hold | $10.50 | N/A | Maintains | 3 years ago |
Lakefront Biotherapeutics NvLKFT | 10 | Hold | $40.00 | N/A | Maintains | 3 years ago |
EVO | 2 | Strong Buy | $16.00 | N/A | Upgrades | 3 years ago |
Evotec SeEVO | 1 | Strong Sell | $16.00 | N/A | Downgrades | 4 years ago |
Ablynx NvABLX | 1 | Strong Buy | $25.00 | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.